SCHEMBL5451255

SCHEMBL5451255

CCc1cccc2c(C(=O)NCc3ccccc3)cn(CCCN3CCN(CCOc4ccc(Cl)c5ccccc45)CC3)c12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.44
PTPN7 P35236 1/20 0.43
LMNA P02545 1/20 0.41
CNR2 P34972 3/20 0.41
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 3/20 0.40
POLB P06746 2/20 0.40
PDE10A Q9Y233 2/20 0.40
MEN1 O00255 1/20 0.40
USP2 O75604 1/20 0.40
MAPK14 Q16539 1/20 0.40
RAB9A P51151 1/20 0.39
BCL2 P10415 1/20 0.39
BCL2L1 Q07817 1/20 0.39
MCL1 Q07820 1/20 0.39
L3MBTL1 Q9Y468 3/20 0.39
GAA P10253 1/20 0.39
HTR1A P08908 1/20 0.39
DRD2 P14416 1/20 0.39
HTR2A P28223 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5453673 0.93 CNR1 (0.44) KMT2ACNR2PDE10AMAPK14HTR1A
SCHEMBL5448583 0.88 KMT2A (0.42) KMT2ACNR2ALDH1A1KDM4EMEN1
SCHEMBL5452038 0.88 PTPN7 (0.57) PTPN7LMNACNR2ALDH1A1KDM4E
SCHEMBL5446675 0.87 PTPN7 (0.51) KMT2APTPN7LMNACNR2ALDH1A1
SCHEMBL5443756 0.85 PTPN7 (0.55) PTPN7LMNACNR2ALDH1A1KDM4E
SCHEMBL5453053 0.85 PTPN7 (0.47) PTPN7CNR2ALDH1A1KDM4EMCL1
SCHEMBL5457236 0.85 PTPN7 (0.56) PTPN7LMNACNR2ALDH1A1KDM4E
SCHEMBL5441597 0.85 PDE10A (0.49) KMT2ACNR2ALDH1A1PDE10AMEN1
SCHEMBL5453562 0.85 PDE10A (0.45) KMT2ACNR2ALDH1A1PDE10AMEN1
SCHEMBL5448781 0.84 PDE10A (0.49) KMT2ACNR2PDE10AMEN1DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070213359-A1 BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF ACADIA PHARMACEUTICALS INC. (US) 2007-09-13 US disclosed
US-20070213359-A1 BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF ACADIA PHARMACEUTICALS INC. (US) 2007-09-13 US disclosed
US-20070213359-A1 BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF ACADIA PHARMACEUTICALS INC. (US) 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213359-A1 BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF GIPR, GHSR, GHRHR KMT2A 4056/4885PTPN7 592/4885LMNA 3791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.